| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||||||
| Brief Title † | Studies of Elevated Parathyroid Activity | ||||||||
| Official Title † | Studies of Hyperparathyroidism and Related Disorders | ||||||||
| Brief Summary | Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism. This study will help researchers better understand the causes of hyperthyroidism and to evaluate and improve methods for diagnosis and treatment. In this study, patients diagnosed with or suspected of having hyperparathyroidism will be selected to participate. In addition, patients with related conditions such as parathyroid tumors, will also be selected. Subjects will be asked to provide blood and urine for testing to confirm their condition. They will then be surgically treated by removal of the parathyroid gland(s) (parathyroidectomy). Subjects with parathyroid tumors will undergo several diagnostic tests to determine the exact location of the tumor as well as the tumor's activity. The tests may include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing. Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are typically the mainstay of post parathyroidectomy therapy. Other potential treatments include transplanting the parathyroid gland(s) to other areas of the body. |
||||||||
| Detailed Description | Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. Patients with moderately severe primary hyperparathyroidism will be treated. The principal diagnostic components are calcium in serum and urine and parathyroid hormone in serum. Treatment will be mainly by parathyroidectomy. Preoperative testing to localize parathyroid neoplasm(s) will be used usually and with more extended methods in cases with prior neck surgery. Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, fine needle aspiration for parathyroid hormone assay, arteriogram, selective venous catheterization for parathyroid hormone assay. Options for management of postoperative hypocalcemia include calcium, vitamin D preparations, parathyroid autografts and synthetic parathyroid hormone. Research specimens may consist of blood or tumors. |
||||||||
| Study Phase | |||||||||
| Study Type † | Observational | ||||||||
| Study Design † | |||||||||
| Primary Outcome Measure † | |||||||||
| Secondary Outcome Measure † | |||||||||
| Condition † | Hyperparathyroidism Hypocalcemia Hypoparathyroidism Parathyroid Neoplasm |
||||||||
| Intervention † | |||||||||
| MEDLINE PMIDs | 9103196, 8523102, 7916660 | ||||||||
| Links | NIH Clinical Center Detailed Web Page  |
||||||||
| Recruitment Information Fields | |||||||||
| Recruitment Status † | Recruiting | ||||||||
| Enrollment † | |||||||||
| Start Date † | March 1991 | ||||||||
| Completion Date | |||||||||
| Eligibility Criteria † |
Patients (male or female any age) with known or suspected primary hyperparathyroidism or a related disorder (such as familial multiple endocrine neoplasia type 1 [FMEN1]) will be evaluated. The vast majority of patients will be greater than age 18. In the rare occasion where special resources might be appropriate (uremic patient, young child), the availability of special resources would be confirmed prior to admission. EXCLUSION CRITERIA: There are no absolute exclusions. |
||||||||
| Gender | Both | ||||||||
| Ages | |||||||||
| Accepts Healthy Volunteers | No | ||||||||
| Contacts †† |
|
||||||||
| Location Countries † | United States | ||||||||
| Administrative Information Fields | |||||||||
| NCT ID † | NCT00001277 | ||||||||
| Organization ID | 910085 | ||||||||
| Secondary IDs †† | 91-DK-0085 | ||||||||
| Study Sponsor † | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||||||||
| Collaborators †† | |||||||||
| Investigators † | |||||||||
| Information Provided By | National Institutes of Health Clinical Center (CC) | ||||||||
| Verification Date | January 2008 | ||||||||
| First Received Date † | November 3, 1999 | ||||||||
| Last Updated Date | July 18, 2008 | ||||||||
|
